

Siao-Yi Wang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/833225/publications.pdf>

Version: 2024-02-01

10
papers

848
citations

1162889

8
h-index

1372474

10
g-index

11
all docs

11
docs citations

11
times ranked

1093
citing authors

#	ARTICLE	IF	CITATIONS
1	HDAC inhibition prevents transgene expression downregulation and loss-of-function in T cell-receptor-transduced T cells. <i>Molecular Therapy - Oncolytics</i> , 2021, 20, 352-363.	2.0	7
2	Melanoma reactive TCR-modified T cells generated without activation retain a less differentiated phenotype and mediate a superior in vivo response. <i>Scientific Reports</i> , 2021, 11, 13327.	1.6	8
3	Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 311-325.	2.0	40
4	miR-19, miR-345, miR-519c-5p Serum Levels Predict Adverse Pathology in Prostate Cancer Patients Eligible for Active Surveillance. <i>PLoS ONE</i> , 2014, 9, e98597.	1.1	41
5	Limited ability of existing nomograms to predict outcomes in men undergoing active surveillance for prostate cancer. <i>BJU International</i> , 2014, 114, E18-E24.	1.3	43
6	Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism. <i>Blood</i> , 2011, 118, 3347-3349.	0.6	117
7	Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model. <i>Blood</i> , 2009, 114, 5322-5330.	0.6	129
8	NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement. <i>Blood</i> , 2008, 111, 1456-1463.	0.6	172
9	Complement and cellular cytotoxicity in antibody therapy of cancer. <i>Expert Opinion on Biological Therapy</i> , 2008, 8, 759-768.	1.4	76
10	Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. <i>Blood</i> , 2006, 108, 2648-2654.	0.6	215